氧化钽纳米粒子作为多功能高分辨率 X 射线造影剂,用于乳腺癌啮齿动物模型的导管内图像引导消融术

Erin K. Zaluzec, Elizabeth Kenyon, Maximilian Volk, Hasaan Hayat, Katherine Powell, Alexander Loomis, Shatadru Chakravarty, Jeremy M. L. Hix, Josh Schipper, Chi Chang, Matti Kiupel, Ping Wang, Erik M. Shapiro, Lorenzo F. Sempere
{"title":"氧化钽纳米粒子作为多功能高分辨率 X 射线造影剂,用于乳腺癌啮齿动物模型的导管内图像引导消融术","authors":"Erin K. Zaluzec, Elizabeth Kenyon, Maximilian Volk, Hasaan Hayat, Katherine Powell, Alexander Loomis, Shatadru Chakravarty, Jeremy M. L. Hix, Josh Schipper, Chi Chang, Matti Kiupel, Ping Wang, Erik M. Shapiro, Lorenzo F. Sempere","doi":"10.1038/s44303-024-00007-5","DOIUrl":null,"url":null,"abstract":"There are limited options for primary prevention of breast cancer (BC). Experimental procedures to locally prevent BC have shown therapeutic efficacy in animal models. To determine the suitability of FDA-approved iodine-containing and various metal-containing (bismuth, gold, iodine, or tantalum) preclinical nanoparticle-based contrast agents for image-guided intraductal (ID) ablative treatment of BC in rodent models, we performed a prospective longitudinal study to determine the imaging performance, local retention and systemic clearance, safety profile, and compatibility with ablative solution of each contrast agent. At least six abdominal mammary glands (>3 female FVB/JN mice and/or Sprague-Dawley rats, 10–11 weeks of age) were intraductally injected with commercially available contrast agents (Omnipaque® 300, Fenestra® VC, MVivoTM Au, MVivoTM BIS) or in-house synthesized tantalum oxide (TaOx) nanoparticles. Contrast agents were administered at stock concentration or diluted in 70% ethanol (EtOH) and up to 1% ethyl cellulose (EC) as gelling agent to assess their compatibility with our image-guided ablative procedure. Mammary glands were serially imaged by microCT for up to 60 days after ID delivery. Imaging data were analyzed by radiologists and deep learning to measure in vivo signal disappearance of contrast agents. Mammary glands and major organs were ultimately collected for histopathological examination. TaOx-containing solutions provided best imaging performance for nitid visualization of ductal tree immediately after infusion, low outward diffusion (<1 day) and high homogeneity. Of all nanoparticles, TaOx had the highest local clearance rate (46% signal decay as stock and 36% as ablative solution 3 days after ID injection) and exhibited low toxicity. TaOx-containing ablative solution with 1% EC caused same percentage of epithelial cell death (88.62% ± 7.70% vs. 76.38% ± 9.99%, p value = 0.089) with similar minimal collateral damage (21.56 ± 5.28% vs. 21.50% ± 7.14%, p value = 0.98) in mouse and rat mammary glands, respectively. In conclusion, TaOx-nanoparticles are a suitable and versatile contrast agent for intraductal imaging and image-guided ablative procedures in rodent models of BC with translational potential to humans.","PeriodicalId":501709,"journal":{"name":"npj Imaging","volume":" ","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44303-024-00007-5.pdf","citationCount":"0","resultStr":"{\"title\":\"Tantalum oxide nanoparticles as versatile and high-resolution X-ray contrast agent for intraductal image-guided ablative procedure in rodent models of breast cancer\",\"authors\":\"Erin K. Zaluzec, Elizabeth Kenyon, Maximilian Volk, Hasaan Hayat, Katherine Powell, Alexander Loomis, Shatadru Chakravarty, Jeremy M. L. Hix, Josh Schipper, Chi Chang, Matti Kiupel, Ping Wang, Erik M. Shapiro, Lorenzo F. Sempere\",\"doi\":\"10.1038/s44303-024-00007-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"There are limited options for primary prevention of breast cancer (BC). Experimental procedures to locally prevent BC have shown therapeutic efficacy in animal models. To determine the suitability of FDA-approved iodine-containing and various metal-containing (bismuth, gold, iodine, or tantalum) preclinical nanoparticle-based contrast agents for image-guided intraductal (ID) ablative treatment of BC in rodent models, we performed a prospective longitudinal study to determine the imaging performance, local retention and systemic clearance, safety profile, and compatibility with ablative solution of each contrast agent. At least six abdominal mammary glands (>3 female FVB/JN mice and/or Sprague-Dawley rats, 10–11 weeks of age) were intraductally injected with commercially available contrast agents (Omnipaque® 300, Fenestra® VC, MVivoTM Au, MVivoTM BIS) or in-house synthesized tantalum oxide (TaOx) nanoparticles. Contrast agents were administered at stock concentration or diluted in 70% ethanol (EtOH) and up to 1% ethyl cellulose (EC) as gelling agent to assess their compatibility with our image-guided ablative procedure. Mammary glands were serially imaged by microCT for up to 60 days after ID delivery. Imaging data were analyzed by radiologists and deep learning to measure in vivo signal disappearance of contrast agents. Mammary glands and major organs were ultimately collected for histopathological examination. TaOx-containing solutions provided best imaging performance for nitid visualization of ductal tree immediately after infusion, low outward diffusion (<1 day) and high homogeneity. Of all nanoparticles, TaOx had the highest local clearance rate (46% signal decay as stock and 36% as ablative solution 3 days after ID injection) and exhibited low toxicity. TaOx-containing ablative solution with 1% EC caused same percentage of epithelial cell death (88.62% ± 7.70% vs. 76.38% ± 9.99%, p value = 0.089) with similar minimal collateral damage (21.56 ± 5.28% vs. 21.50% ± 7.14%, p value = 0.98) in mouse and rat mammary glands, respectively. In conclusion, TaOx-nanoparticles are a suitable and versatile contrast agent for intraductal imaging and image-guided ablative procedures in rodent models of BC with translational potential to humans.\",\"PeriodicalId\":501709,\"journal\":{\"name\":\"npj Imaging\",\"volume\":\" \",\"pages\":\"1-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/s44303-024-00007-5.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"npj Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.nature.com/articles/s44303-024-00007-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"npj Imaging","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44303-024-00007-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

乳腺癌(BC)一级预防的选择有限。局部预防乳腺癌的实验程序已在动物模型中显示出疗效。为了确定 FDA 批准的含碘和各种含金属(铋、金、碘或钽)的临床前纳米粒子造影剂是否适合在啮齿类动物模型中对 BC 进行图像引导的导管内(ID)消融治疗,我们进行了一项前瞻性纵向研究,以确定每种造影剂的成像性能、局部保留和全身清除率、安全性以及与消融溶液的兼容性。在至少六个腹部乳腺(>3 只雌性 FVB/JN 小鼠和/或 Sprague-Dawley 大鼠,10-11 周龄)导管内注射市售造影剂(Omnipaque® 300、Fenestra® VC、MVivoTM Au、MVivoTM BIS)或内部合成的氧化钽(TaOx)纳米颗粒。造影剂以原液浓度或用 70% 的乙醇(EtOH)稀释,并用最高 1% 的乙基纤维素(EC)作为胶凝剂,以评估它们与我们的图像引导消融程序的兼容性。在注射 ID 后的 60 天内,用显微 CT 对乳腺进行连续成像。放射科医生对成像数据进行分析,并通过深度学习来测量造影剂在体内的信号消失情况。最终收集乳腺和主要器官进行组织病理学检查。含 TaOx 的溶液在输注后立即对导管树进行硝化显像方面具有最佳成像性能、低向外扩散(<1 天)和高均匀性。在所有纳米粒子中,TaOx 的局部清除率最高(ID 注射 3 天后,原液的信号衰减率为 46%,消融溶液的信号衰减率为 36%),而且毒性低。含 1%氨基甲酸乙酯的 TaOx 消融液在小鼠和大鼠乳腺中分别造成相同比例的上皮细胞死亡(88.62% ± 7.70% vs. 76.38% ± 9.99%,p 值 = 0.089)和相似的最小附带损伤(21.56 ± 5.28% vs. 21.50% ± 7.14%,p 值 = 0.98)。总之,TaOx 纳米粒子是一种适用于乳腺癌啮齿动物模型导管内成像和图像引导消融术的多功能造影剂,具有向人类转化的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Tantalum oxide nanoparticles as versatile and high-resolution X-ray contrast agent for intraductal image-guided ablative procedure in rodent models of breast cancer
There are limited options for primary prevention of breast cancer (BC). Experimental procedures to locally prevent BC have shown therapeutic efficacy in animal models. To determine the suitability of FDA-approved iodine-containing and various metal-containing (bismuth, gold, iodine, or tantalum) preclinical nanoparticle-based contrast agents for image-guided intraductal (ID) ablative treatment of BC in rodent models, we performed a prospective longitudinal study to determine the imaging performance, local retention and systemic clearance, safety profile, and compatibility with ablative solution of each contrast agent. At least six abdominal mammary glands (>3 female FVB/JN mice and/or Sprague-Dawley rats, 10–11 weeks of age) were intraductally injected with commercially available contrast agents (Omnipaque® 300, Fenestra® VC, MVivoTM Au, MVivoTM BIS) or in-house synthesized tantalum oxide (TaOx) nanoparticles. Contrast agents were administered at stock concentration or diluted in 70% ethanol (EtOH) and up to 1% ethyl cellulose (EC) as gelling agent to assess their compatibility with our image-guided ablative procedure. Mammary glands were serially imaged by microCT for up to 60 days after ID delivery. Imaging data were analyzed by radiologists and deep learning to measure in vivo signal disappearance of contrast agents. Mammary glands and major organs were ultimately collected for histopathological examination. TaOx-containing solutions provided best imaging performance for nitid visualization of ductal tree immediately after infusion, low outward diffusion (<1 day) and high homogeneity. Of all nanoparticles, TaOx had the highest local clearance rate (46% signal decay as stock and 36% as ablative solution 3 days after ID injection) and exhibited low toxicity. TaOx-containing ablative solution with 1% EC caused same percentage of epithelial cell death (88.62% ± 7.70% vs. 76.38% ± 9.99%, p value = 0.089) with similar minimal collateral damage (21.56 ± 5.28% vs. 21.50% ± 7.14%, p value = 0.98) in mouse and rat mammary glands, respectively. In conclusion, TaOx-nanoparticles are a suitable and versatile contrast agent for intraductal imaging and image-guided ablative procedures in rodent models of BC with translational potential to humans.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Stratifying vascular disease patients into homogeneous subgroups using machine learning and FLAIR MRI biomarkers Metabolic nanoscopy enhanced by experimental and computational approaches Ultrahigh-field animal MRI system with advanced technological update Automated analysis of ultrastructure through large-scale hyperspectral electron microscopy Evaluation of the redox alteration in Duchenne muscular dystrophy model mice using in vivo DNP-MRI
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1